Ipca Laboratories Limited
IPCALAB
Classificação em ações
#3404
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Preço da ação
$20.02
Última sincronização: 2026-10-19
Valor de mercado
$5.08B
Variação (1 dia)
-1.65%
Variação (1 ano)
38.46%
País
IN
Negociar Ipca Laboratories Limited (IPCALAB)
Categoria
Healthcare
Lucros da Ipca Laboratories Limited (IPCALAB)
Lucros em Jun 2026 TTM: $200.02M
De acordo com os últimos relatórios financeiros da Ipca Laboratories Limited, os ganhos atuais da empresa são de $200.02M. Em 2024, a empresa teve ganhos de $100.31M, um aumento em relação a aos ganhos de 2023, que foram de $89.11M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Ipca Laboratories Limited de 2005 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $200.02M | 51.54% |
| 2025 | $131.99M | 31.59% |
| 2024 | $100.31M | 12.56% |
| 2023 | $89.11M | -39.31% |
| 2022 | $146.83M | -22.19% |
| 2021 | $188.69M | 92.38% |
| 2020 | $98.08M | 24.63% |
| 2019 | $78.69M | 76.36% |
| 2018 | $44.62M | 10.42% |
| 2017 | $40.41M | 135.71% |
| 2016 | $17.14M | -69.96% |
| 2015 | $57.08M | -45.77% |
| 2014 | $105.26M | 26.12% |
| 2013 | $83.46M | 16.17% |
| 2012 | $71.85M | -6.02% |
| 2011 | $76.45M | 28.95% |
| 2010 | $59.28M | 154.37% |
| 2009 | $23.31M | -46.79% |
| 2008 | $43.80M | 23.03% |
| 2007 | $35.60M | 112.82% |
| 2006 | $16.73M | -22.39% |
| 2005 | $21.55M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 782.18% |
IN
|
